veriNOS pharmaceuticals

📍 Wuerzburg, Germany🗓 Founded 2022👥 6 employees💰 Last funded Jan 2023
Pharmaceutical Manufacturing🌐 verinos-pharma.com
Website LinkedIn
At veriNOS pharmaceuticals GmbH, we focus on the clinical development of a drug that specifically inhibits a defined cascade that is relevant and common in different disease settings. The activation of iNOS with subsequent excessive production of cell damaging radicals and massive excitotoxic glutamate increase is of crucial importance in all of our indications of interest. Our goal of using Ronopterin is to selectively inhibit upregulated iNOS to reduce radicals and excitotoxic glutamate levels. Our management team consists of experienced biopharma executives with complementary backgrounds, including corporate governance, finance, medicine and science.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2022
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in veriNOS pharmaceuticals?
veriNOS pharmaceuticals has 1 investors on record on gritt.io, including 1 early-stage backers.
When did veriNOS pharmaceuticals last raise funding?
The most recent investment in veriNOS pharmaceuticals recorded on gritt.io was in January 2023.
When was veriNOS pharmaceuticals founded?
veriNOS pharmaceuticals was founded in 2022.
What industry is veriNOS pharmaceuticals in?
veriNOS pharmaceuticals operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is veriNOS pharmaceuticals based?
veriNOS pharmaceuticals is headquartered in Wuerzburg, Germany.